Status:
RECRUITING
Characterization of the Mechanisms of Resistance to Azacitidine
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia
Eligibility:
All Genders
18+ years
Brief Summary
Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71 years). IPSS classification defines low risk (Low and Intermediate 1), and high risk (Intermediate 2 and High)...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- High Risk or Intermediate 2 MDS (IPSS)
- AML-MD (WHO classification)
- Treatment with minimum three to six cycles of Azacitidine
- Informed consent form signed
Exclusion
- Treatment with others chemotherapies alone or in association
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT01210274
Start Date
September 1 2010
End Date
September 1 2025
Last Update
March 19 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
CH d'Antibes
Antibes, France
2
CHU de Nice - Hôpital de l'Archet
Nice, France, 06200
3
Centre Antoine Lacassagne
Nice, France
4
CH Princesse Grace
Monaco, Monaco